The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List


Tue, Mar 4, 10:00 AM, Zacks
Synageva 4Q Loss Narrower-than-Expected Loss - Analyst Blog
Synageva BioPharma Corp. (GEVA) reported fourth quarter 2013 loss of $1 per share, wider than the year-ago loss of 62 cents per share, but narrower than the Zacks Consensus Estimate of a loss of $1.02 per share.

Thu, Feb 20, 8:21 AM, Zacks
Synageva BioPharma Corp. (GEVA) in Focus: Stock Moves 5.1% Higher - Tale of the Tape
Synageva BioPharma Corp. (GEVA) was a big mover last session, as the company saw its shares rise by over 5% on the day.

Synageva BioPharma Corp (GEVA)

Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products. Its lead program, sebelipase alfa, is a recombinant human lysosomal acid lipase (LAL) under clinical investigation for the treatment of patients with early onset and late onset LAL Deficiency. In addition to sebelipase alfa, Co. is investigating protein therapeutic programs for other diseases, which are at different stages of preclinical development. These include two enzyme replacement therapies for other lysosomal storage disorders and additional programs for other life-threatening conditions.

Company Name:  Synageva BioPharma Corp
Sector:  Biotechnology
Number of ETFs Holding GEVA:  21
Total Market Value Held by ETFs:  $100.89M
Total Market Capitalization:  $2.44B
% of Market Cap. Held by ETFs:  4.13%
April 21, 2014    11:53 AM Eastern

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Trade GEVA Now:

Buy (3.44 out of 4)
60th percentile
(ranked higher than approx. 60% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Synageva BioPharma Corp (GEVA) Page | The Online Investor | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.